1970.8000 -26.30 (-1.32%)
NSE Sep 25, 2026 15:31 PM
Volume: 263.8K
 

1970.80
-1.32%
Emkay
Ipca’s 4QFY26 EBITDA was ahead of our expectations (broadly in line with the consensus’). The beat was driven by higher overall sales, a marginally higher gross margin, as well as lower staff costs.
Ipca Laboratories has gained 25.53% in the last 6 Months
More from Ipca Laboratories Ltd.
Recommended